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Abstract
Vesicular stomatitis virus (VSV) is a candidate for development for cancer therapy. It is an oncolytic virus that is safe in humans.
Recombinant virus can be made directly from plasmid components. We attempted to create a virus that targeted specifically to breast cancer
cells. Nonreplicating and replicating pseudotype VSV were created whose only surface glycoprotein (gp) was a Sindbis gp, called
Sindbis-ZZ, modified to severely reduce its native binding function and to contain the Fc-binding domain of Staphylococcus aureus protein
A. When titered on Her2/neu overexpressing SKBR3 human breast cancer cells, pseudotype VSV coated with Sindbis-ZZ had1% the titer
of pseudotype VSV coated with wild-type Sindbis gp. Titer was increased 50-fold when the Sindbis-ZZ pseudotype was conjugated with
4D5, a mouse monoclonal antibody directed against the Her2/neu receptor. Titers of antibody-conjugated virus were increased 36-fold on
a second human breast cancer cell line, MCF7/H2, which expressed lower concentrations of Her2/neu receptor on the cell surface. At
multiple concentrations of antibody, titers on SKBR3 cells were significantly greater when the virus was incubated with Herceptin, an
antibody with a human Fc, than with 4D5, a mouse antibody, reflecting the known higher affinity of the protein A Fc-binding domain for
human Fc. Analysis of the protein composition of the pseudotype VSV found low expression of the modified Sindbis gp on the virus
accounting, in part, for a viral titer that did not exceed 1.2  105/ml. This work demonstrates the ability to easily create, directly from
plasmid components, an oncolytic replicating VSV with a restricted host cell range.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Viruses and viral vectors that kill specific cells are being
designed for cancer therapy (Wildner, 2001; Ring, 2002;
Russell, 1994; Zwiebel, 2001). Important issues are effi-
cacy, selectivity, and host response to the virus. Adenovirus
and herpesvirus have been used most extensively. A wide
variety of tumor types have been targeted with viruses that
are replication competent, conditionally competent, or in-
competent. The viruses may be directly cytolytic or may
incorporate extra genes that promote toxic, apoptotic, or
immunologically mediated cell death. Selectivity can be
achieved by specific binding of the virus to the target cell,
by special properties of the cancer cell such as p53 or p21
deficiency, or by use of cell specific promoters to express
essential viral genes.
Our goal was to create a vesicular stomatitis virus (VSV)
that targeted to Her2/neu overexpressing breast cancer cells.
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VSV represents an excellent candidate for cancer therapy
because it is an efficient cell killer with selectivity for
cancer cells that is safe in humans (de Mattos CA et al.,
2001). The Her2/neu receptor is an excellent target because
it is overexpressed in 25–30% of human breast cancers and
is a critical contributor to an aggressive tumor phenotype
(Slamon et al., 2001). Wild-type (wt) VSV has eradicated
established tumors in mice when injected intratumorally or
intravenously (Balachandran et al., 2001; Fernandez et al.,
2002). Selectivity was based on the absence of an interferon
response in the tumor cells (Stojdl et al., 2000; Rose and
Whitt, 2001). We attempted to further develop VSV for
clinical use in cancer therapy by restricting its host range to
cells that overexpress the Her2/neu receptor. VSV is an
enveloped virus with a single surface glycoprotein (gp)
called G that fully determines binding of the virus as well as
promoting pH-dependent fusion of the virus envelope with
cell membranes (Rose and Whitt, 2001). The receptor for G
is ubiquitous and VSV promiscuously infects most cell
types. Attempts to modify G binding were unsuccessful
because the site of the binding domain within the G protein
and the structure of the G protein are unknown. On the other
hand a binding defective mutant of Sindbis virus has already
been identified (Dubuisson and Rice, 1993). The surface gp
of Sindbis consists of an E1 fusion protein and an E2
binding protein. Deletion of amino acids 72 and 73 within
E2 reduces binding and infectivity of the virus 90% (Du-
buisson and Rice, 1993). Antibody-directed targeting of
Sindbis and retroviral vectors was achieved when the Sind-
bis gp gene was modified at this site to encode two synthetic
immunoglobulin G (IgG) Fc-binding domains called ZZ
derived from protein A of the Staphylococcus aureus spa
gene (Ohno et al., 1997; Sawai and Meruelo, 1998; Mori-
zono et al., 2001). We demonstrate in this article that when
this ZZ-modified Sindbis gp coats VSV, an infectious virus
can be selectively targeted to Her2/neu-amplified breast
cancer by monoclonal antibodies directed to the Her2/neu
receptor.
Results
Pseudotype VSV coated with Sindbis-ZZ gp infects Her2/
neu overexpressing cells in an antibody-dependent
manner
Our goal was to develop VSV for clinical use in cancer
therapy by restricting its host range to cells that overexpress
the Her2/neu receptor. To this end, a recombinant VSV
(rVSV) genome was constructed in which the G gene was
replaced by a gene encoding green fluorescent protein
(EGFP-G/XN2). This construct was used to create a non-
replicating virus whose genome consisted of rVSV-
EGFP-G and whose surface protein, supplied in trans by
transfection, was either VSV-G, wt Sindbis, or Sindbis-ZZ
(Lawson et al., 1995). Titers of these viruses were easily
determined by infecting a target cell line and counting green
cells 1 day later. The titer of pseudotype VSV-EGFP-G
coated with Sindbis-ZZ was determined on the Her2/neu
naturally overexpressing cell line, SKBR3, both in the pres-
ence and in the absence of 4D5, a mouse antibody directed
to the Her2/neu receptor. Titers were 50-fold higher when
virus was incubated prior to infection with 4D5 (Fig. 1).
Improvement in titer was directly related to the concentra-
tion of antibody incubated with the virus (Fig. 1). Maximum
titers on SKBR3 cells were achieved at antibody concen-
trations of 20 g/ml and concentrations of 100 g/ml did
not improve yield. Titers were not improved when the target
cells were incubated with antibody during viral infection.
Titers were directly related to the amount of Her2/neu
receptor on the target cell. MCF7 is a human breast cancer
line that does not overexpress the Her2/neu receptor and
titers of pseudotype VSV-EGFP-G coated with Sindbis-ZZ
on this cell line were undetectable. MCF7/H2 are MCF7
cells that have been stably transfected with multiple copies
of the Her2/neu gene and overexpress the receptor on the
cell surface but to a lesser extent than SKBR3 as has
previously been shown by this laboratory (Bergman et al.,
2001). Titers of pseudotype VSV-EGFP-G coated with
Sindbis-ZZ on this cell line were also directly related to the
concentration of 4D5 incubated with the virus but were
lower than the titers achieved on the SKBR3 cell line (Fig.
1). Two-color flow cytometric analysis demonstrated that
when antibody targeted pseudotype VSV-EGFP-G coated
with Sindbis-ZZ was incubated with a mixed culture of
SKBR3 and MCF7, 94% of the infected cells were Her2/neu
overexpressing SKBR3 (Fig. 2, upper right quadrant). An-
tibody dependence was demonstrated not only by improved
titer with higher concentrations of antibody, as noted in Fig.
1, but also by improved titer when human antibody was
used in place of mouse antibody. Titers on SKBR3 of
pseudotype VSV-EGFP-G coated with Sindbis-ZZ were at
least fourfold greater when the virus was incubated with a
humanized form of 4D5 called Herceptin than with the
original mouse antibody (Fig. 3). The antigen-binding re-
gions of Herceptin and 4D5 are identical but the Fc portion
of Herceptin is human and the Fc portion of 4D5 is mouse
IgG1. The Fc binding of Sindbis-ZZ is derived from S.
aureus Protein A, which binds human Fc better than mouse
(Lindmark et al., 1983). The cytopathic effect of recombi-
nant VSV was measured in low and high Her2/neu-express-
ing cells and based on trypan blue exclusion 1 day after
infection at multiplicity of infection (m.o.i.)  10 was
92.1% in SKBR3 cells and 4.7% in 143 cells.
Pseudotype VSV-EGFP-G coated with Sindbis-ZZ
could be easily concentrated 40- to 60-fold by ultracentrif-
ugation (Sorvall Ultra 80 pro with T860 rotor at 79,000 g for
90 min) or filtration (Millipore UFV4BTK25 Ultrafree-4
Centrifugal Filter Device Biomax 30K NMWL Membrane).
Further concentration was not attempted. Ultracentrifuga-
tion concentrated the virus from a titer of 1.1  104/ml to a
titer of 4.1  105/ml with a 42% recovery rate. Filtration
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concentrated the virus from a titer of 1.6  104/ml to a titer
of 1  106/ml with a 27% recovery rate.
Recombinant replication-competent VSV coated with
Sindbis-ZZ gp also infects Her2/neu overexpressing cells
in an antibody-dependent manner
A replication-competent VSV was created which con-
tained the gene expressing Sindbis-ZZ in the viral genome
and whose only coat protein was Sindbis-ZZ. This virus
showed targeted infection of Her2/neu-expressing SKBR3
cells when combined with antibodies directed to the Her2/
neu receptor (Fig. 4). The humanized antibody Herceptin
was more effective than the mouse antibody 4D5. These
antibodies did not improve infection of the virus toward a
cell line, 143, that does not express the Her2/neu receptor
(Fig. 4). Similar selective infection was seen of a mouse
mammary tumor line, D2F2/E2, that had been stably trans-
fected to express Her2/neu when compared with infection of
the parental cell line, D2F2 (Fig. 4). This virus combined
with Herceptin also displayed targeted replication within
Her2/neu-expressing SKBR3 cells (Fig. 5).
Comparison of VSV-EGFP-G coated with either Sindbis-
ZZ, wt Sindbis, or VSV-G
Titer
The infectivity on Her2/neu overexpressing SKBR3 cells
of VSV-EGFP-G coated with either G, Sindbis, Sindbis-
ZZ, or uncoated was compared (Fig. 6). Removal of G from
the surface of the viral particle and substitution with Sind-
bis-ZZ severely curtailed but did not eliminate nonspecific
infection. Pseudotype VSV coated with Sindbis-ZZ had
1% the titer of pseudotype VSV coated with wild-type
Sindbis gp. However, even without antibody, the titer of
VSV-EGFP-G coated with Sindbis-ZZ gp was one log
greater than the titer of control VSV-EGFP-G created
without a surface gp. This residual binding function came
Fig. 1. Titer on two Her2/neu overexpressing cell lines of VSV-EGFP-G coated with Sindbis-ZZ and targeted with various concentrations of the
anti-Her2/neu receptor antibody, 4D5. Mean of three experiments with standard error bars.
Fig. 2. Two-color flow cytometric analysis of a mixture of SKBR3 and
MCF7 cells infected with 4D5-targeted VSV-EGFP-G coated with Sind-
bis-ZZ. Infected cells are positive for FL1-fitc (right quadrants). Her2/neu
overexpressing cells are positive for FL2-PE (upper quadrants). Infected
cells that are also Her2/neu overexpressing are found in the upper right
quadrant and represent 94% of infected cells.
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Fig. 3. Comparison of titer on Her2/neu overexpressing SKBR3 cells of VSV-EGFP-G coated with Sindbis-ZZ when targeted with either mouse antibody,
4D5, or humanized antibody, Herceptin. Mean of three experiments with standard error bars.
Fig. 4. Titer on two pairs of cell lines of recombinant replication-competent VSV coated only with Sindbis-ZZ and targeted with either mouse antibody, 4D5,
humanized antibody, Herceptin, or no antibody. SKBR3 and D2F2/E2 are Her2/neu overexpressing cell lines. Mean of three experiments with standard error
bars.
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Fig. 5. Growth of replicating recombinant VSV expressing Sindbis-ZZ gp with and without Herceptin in SKBR3 cells that express Her2/neu and 143 cells
that do not.
Fig. 6. Comparison of titer on Her2/neu overexpressing SKBR3 breast carcinoma cells of various VSV pseudotypes. Mean of two to four experiments with
standard error bars. Dashed line represents background G pseudotype (see Materials and methods).
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from the E2 Sindbis gp because it was inhibited 90% by
VR1248, an antibody known to neutralize E2. The baseline
titer of the control VSV-EGFP-G created without a surface
gp was eliminated by incubation of the virus with I14, a
mouse monoclonal antibody directed to the VSV G gp. This
titer therefore presumably represented residual inoculum
virus used in the producer cells to create these various
pseudotypes. As expected, incubation with antibody 4D5
improved the titer of virus coated with Sindbis-ZZ but not
virus coated with wt Sindbis.
Electron microscopy
Pseudotype VSV-EGFP-G coated with either VSV-G,
wt Sindbis, or Sindbis-ZZ were bullet-shaped particles sim-
ilar in size and morphology to wt VSV virus (data not
shown).
Number and stability of viral particles
Quantitative real-time RT-PCR demonstrated that the
concentration of viral genomes was similar in pseudotype
VSV-EGFP-G coated with either Sindbis-ZZ, wt Sindbis,
or VSV-G (Fig. 7). Differences in viral titer therefore re-
flected differences in infectivity and not differences in viral
production. There was no change in cycle time (Ct), a
measure of the concentration of viral genomes, following
incubation of the viruses with RNaseA, 1 g/ml for 30 min
at 37°C, eliminating the possibility that the PCR was am-
plifying cellular RNA. Two freeze/thaw cycles of the virus
produced no change in titer for pseudotype VSV coated
with VSV-G and slightly less than 40% loss of titer for
pseudotypes coated with wt Sindbis and Sindbis-ZZ.
Endosomal pH dependence
Bafilomycin A1, a macrolide antibiotic, is a specific
inhibitor of vacuolar-type H-ATPase that blocks acidifi-
cation of the endosome. Titers of the VSV pseudotypes on
SKBR3 cells were determined in the presence of 30 nM
Bafilomycin. Bafilomycin blocked 99% of infection with
all three pseudotypes: VSV-EGFP-G coated with either
VSV-G, wt Sindbis, or Sindbis-ZZ (Fig. 8). Sindbis-ZZ was
preincubated with mouse monoclonal antibody 4D5, 20
g/ml. Although G, Sindbis, and Sindbis-ZZ bound to dif-
ferent cellular receptors, all required acidification of the
endosome to allow viral envelope fusion with the plasma
membrane. As a control, a VSV pseudotype was con-
structed expressing the F and HN glycoproteins from the
paramyxovirus SV5. SV5 F and HN promote entry of the
virus directly through the plasma membrane and are not
affected by endosomal pH. Bafilomycin (30 nM) did not
block infection of this pseudotype at all (0% inhibition).
Fig. 7. Quantitative RT-PCR of pseudotype VSV-EGFP-G coated with either VSV-G, wt Sindbis, or Sindbis-ZZ. Ct represents the cycle number required
to achieve a threshold concentration of fluorescence.
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Surface expression of glycoprotein
Radiolabeling of viral proteins demonstrated gp bands in
the pseudotype nonreplicating viruses coated with VSV-G
and with wt Sindbis but no gp band was seen in the
pseudotype coated with modified Sindbis-ZZ (Fig. 9A). The
density of the N, M, and L protein bands in the viruses
coated with wt Sindbis and Sindbis-ZZ were comparable,
indicating that a similar number of virus particles were
assayed. The number of methionine amino acids in VSV-G,
Sindbis E1, and Sindbis E2 are also comparable. Radiola-
beling of viral proteins in the recombinant replicating VSV
whose only surface gp was Sindbis-ZZ demonstrated a faint
gp band (Fig. 9B).
Discussion
We have demonstrated the ability to create a targeted
VSV virus using a new methodology (Schnell et al., 1997;
Johnson et al., 1997). Pseudotype nonreplicating and re-
combinant replicating VSV were made whose surface mol-
ecule was a modified Sindbis glycoprotein containing spe-
cific binding sites for the Fc portion of IgG. The replicating
virus contained the gene for Sindbis-ZZ in the VSV ge-
nome, whereas the nonreplicating virus did not contain any
gp gene. In the nonreplicating virus, the gp was supplied in
trans by transfection of a plasmid expressing it. These
viruses were selectively targeted to Her2/neu-amplified hu-
man breast cancer in the presence of monoclonal antibodies
directed to the Her2/neu receptor. Titers were higher in the
presence of an antibody with a human Fc presumably be-
cause human Fc binds better to Staphylococcus Protein A
than mouse Fc (Lindmark et al., 1983). These viruses could
be targeted to any cell with a specific antigen on its surface.
They may be useful in purging specific cell populations in
vitro. However, the potential use of these viruses in the
clinic is limited because the titers are low and because
targeting requires that a specific antibody attaches to a
nonspecific antibody combining site on the viral surface. In
vivo competition for this nonspecific site will include the
large pool of host IgG antibodies. Nonetheless these tar-
geted viruses establish a method to restrict the host range of
VSV. Fusion was provided by the Sindbis E1 molecule and
binding by the synthetic Fc-binding domains. It may now be
possible to substitute other synthetic binding domains with
a wide variety of specificities to function in combination
with the Sindbis E1 fusion function. Pseudotype VSV
coated with Sindbis-ZZ retained a small degree of infectiv-
ity in the absence of antibody, indicating that not all of the
native Sindbis binding function had been eliminated. How-
ever, knowledge of the structure of Sindbis gp suggests sites
for further mutations to abrogate this residual activity
(Zhang et al., 2002). Although several viruses including
paramyxoviruses produce pairs of surface molecules which
separate the binding and fusion function, these pairs of
Fig. 8. Inhibition by 30 nM of Bafilomycin A1 on titer on SKBR3 cells of pseudotype VSV-EGFP-G coated with either VSV-G, wt Sindbis, or Sindbis-ZZ.
Sindbis-ZZ was preincubated with mouse monoclonal antibody 4D5, 20 g/ml. Mean of three experiments with standard error bars.
343I. Bergman et al. / Virology 316 (2003) 337–347
molecules appear closely adapted to each other and it has
not yet been possible to make an infective chimeric virus
that uses the fusion protein of one of these pairs with a new
synthetic binding protein. Separation of binding and fusion
functions may be more difficult in viruses that enter the
target cell through the plasma membrane such as paramyxo-
viruses and retroviruses than viruses that enter through the
endosome such as Sindbis (Lamb and Kolakofsky, 2001). In
the former, binding triggers fusion and may be inextricably
linked to it, whereas in the latter, low pH triggers fusion and
binding may be a more isolatable function. This work dem-
onstrates the ability to easily create, directly from plasmid
components, an oncolytic replicating VSV with a restricted
host cell range.
The low titer of pseudotype VSV coated with Sindbis-ZZ
was not caused by failure to produce viral particles or lack
of stability of the particles. Quantitative real-time RT-PCR
demonstrated that the concentration of viral RNA genomes
was very similar in pseudotype VSV coated with either
Sindbis-ZZ, wt Sindbis, or VSV-G. Particles were resistant
to RNase A and freeze/thaw. These findings are consistent
with previous work showing efficient budding of recombi-
nant VSV expressing chimeric G proteins with the trans-
membrane and cytoplasmic domains derived from the hu-
man CD4 protein (Schnell et al., 1996). A cytoplasmic
domain of at least 9 amino acids was required but there was
no requirement for a specific sequence in that domain
(Schnell et al., 1998). Analysis of the protein composition of
the nonreplicating and replicating pseudotype VSV coated
with Sindbis-ZZ indicated that one cause of the low titer
was low concentration of Sindbis-ZZ on the virus. Sind-
bis-ZZ gp is a synthetic chimeric protein with no natural
counterpart that either may not traffic easily through the
cellular endoplasmic reticulum and golgi apparatus to the
plasma membrane or may not be efficiently incorporated
into the viral envelope.
Materials and methods
Cells, antibodies, and chemicals
The human mammary adenocarcinoma cell lines SKBR3
and MCF7, the simian kidney cell line COS-7, and the
hamster kidney cell line BHK-21 (obtained from American
Type Culture Collection (ATCC), Rockville, MD) were
grown using standard tissue culture techniques in a humid-
ified incubator at 37°C with 5% CO2. SKBR3 cells are
known HER2/neu-amplified/overexpressing breast cancer
cells, whereas MCF7 do not contain HER2/neu amplifica-
tion and express low amounts of the receptor (Bergman et
al., 2001). MCF7/H2 cells are MCF7 cells stably transfected
with a vector expressing the human Her2/neu gene and were
a generous gift from Dr. Dennis J. Slamon (University of
California, Los Angeles Medical School). D2F2/E2 are a
mouse mammary tumor line that has been stably transfected
with a vector expressing the human Her2/neu gene and were
a generous gift from Dr. Wei-Zen Wei (Karmanos Cancer
Institute, Wayne State University, Detroit, MI). Absence of
mycoplasma contamination in all cell lines was confirmed
by the Gen-Probe rapid detection system (Gen-Probe Inc.,
San Siego, CA). MAb 4D5, a mouse monoclonal antibody
directed to the Her2/neu receptor, was provided by Genen-
tech, Inc. (South San Francisco, CA). I14, a mouse mono-
clonal antibody directed to the VSV G protein, was a gen-
Fig. 9. A compares the density of sucrose-gradient purified radiolabeled
viral proteins bands from wt VSV (lane 1) and pseudotype VSV-EGFP-G
coated with either Sindbis-ZZ (lane 2), wt Sindbis (lane 3), VSV-G (lane
4), or no glycoprotein (lane 5). Lane 6 was a no virus control. B compares
the density of radiolabeled viral proteins bands from recombinant replicat-
ing VSV whose only surface gp was Sindbis-ZZ (lane 7) and wt VSV (lane
8).
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erous gift of Dr. Douglas S. Lyles (Wake Forest University
School of Medicine). VR1248, a mouse polyclonal antibody
directed to the Sindbis virus, was obtained from ATCC.
Bafilomycin A1 was obtained from Kamiya Biomedical Co.
(Seattle, WA). RNase A was obtained from Ambion, Inc.
(Cat. No. 2272, Austin, TX).
Flow cytometry
Flow cytometry was performed by incubating 5  105–1
 106 cells with 100 l of antibody and then staining with
a R-Phycoerythrin-conjugated goat anti-mouse IgG anti-
body (Sigma P9670, St. Louis, MO). Immunofluorescence
was quantitated using a FACStarPlus cytometer (Becton
Dickinson, Mountainview, CA).
Electron microscopy
Pseudotype viruses were adhered to 200 mesh copper
grids (G200-Cu, Electron Microscopy Sciences, Fort Wash-
ington, PA) and fixed in 2% glutaraldehyde as previously
described (Atchison, 1970). Sections were then stained with
1% (w/v) aqueous phosphotungstic acid (PTA), pH 7.2 and
observed on a JEOL JEM 1210 electron microscope (Pea-
body, MA) at 80 kV.
Quantitative real-time RT-PCR
The following primers were constructed to amplify a
77-nt internal region of the VSV M gene: GCGGTATTG-
GCAGATCAAGGT and CCCCATCCTATGTGGCAAAT.
The following primer probe conjugated with 56-FAM/3
Black Hole-1 fluorogen and quencher was purchased from
Integrated DNA Technologies, Inc. (Coralville, IA): AC-
CAGAGTATCACACTCACTGCGAAGGCA. Viral RNA
was isolated using the QiaAmp Viral RNA extraction kit
(Qiagen, Inc., Valencia, CA) and amplified in a one-step
RT-PCR reaction using Taqman Gold RT-PCR kit contain-
ing multiscribe reverse transcriptase and Amplitaq Gold (PE
Applied Biosystems, Foster City, CA). Results were ana-
lyzed on an ABI Prism 7700 Sequence Detector (PE Ap-
plied Biosystems).
Vectors, VSV pseudotypes, and titer determination
Vectors expressing the VSV genome (XN2) and the
individual VSV genes P, L, N, and G (pBS-P, L, N, and G,
respectively) on a T7 promoter were a very generous gift of
Dr. John K. Rose (Yale University School of Medicine). A
vector expressing VSV-G on a CMV promoter (CMV-
VSV-G) was a generous gift of Dr. Paul D. Robbins (Uni-
versity of Pittsburgh School of Medicine). Vectors express-
ing Sindbis gp (Sindbis) and Sindbis gp modified between
amino acids 71 and 74 to express two IgG binding domains
(Sindbis-ZZ) were generously supplied by Dr. Irvin S.Y.
Chen (University of California, Los Angeles Medical
School). Vectors expressing the SV5 glycoproteins F and
HN were generously supplied by Dr. Robert A. Lamb (Howard
Hughes Medical Institute, Northwestern University).
A recombinant VSV (rVSV) genome was constructed in
which the G gene was replaced by a gene encoding green
fluorescent protein (EGFP-G/XN2). The EGFP gene was
amplified using the forward primer ACGCGTCACTATG-
GTGAGCAAGGGCGAGGA, which added an MluI restric-
tion site (bold) and the reverse primer GCTAGCCGT-
GATATCTGTTAGTTTTTTTCATACTGAGTTACTTGTAC-
AGCTCGTCC, which added an NheI restriction site (bold)
and VSV transcription stop and start signals (italics). This
construct was used to create a nonreplicating virus whose
genome consisted of rVSV-EGFP-G and whose surface
protein was G (Lawson et al., 1995) In brief, EGFP-G/
XN2, pBS-P, pBS-L, pBS-N, and pBS-G were transfected
into COS-7 cells and infected with vTF-7, a vaccinia virus
expressing T7 polymerase (NIH AIDS Research and Ref-
erence Reagent Program, Rockville, MD). Virus were har-
vested from the supernatant 2 days later and amplified on
BHK-21 cells that were transfected with CMV-VSV-G us-
ing a standard lipofectamine protocol.
Nonreplicating pseudotype VSV were created by trans-
fecting BHK-21 with DNA encoding either Sindbis gp or
Sindbis-ZZ gp and 2 days later infecting with rVSV-
EGFP-G at an m.o.i. of 6. Cells were cultured in DMEM
and 10% fetal calf serum with very low IgG (Gibco/BRL,
Cat. No. 16250086, Carlsbad, CA). Supernatant was har-
vested 1 day following infection and stored at 70°C.
Titers were determined by incubating virus and indicator
cell line in one well of a six-well tray (Corning Inc., Cat.
No. 3516, Corning, NY) for 2 h, washing, and replacing the
media. Green cells were counted in an inverted fluorescent
microscope (Axiovert 135, Carl Zeiss, Inc., Thornwood,
NY) 1 day later.
Similar techniques were used to create a recombinant
replicating VSV whose surface gp was Sindbis-ZZ. First,
the gene for Sindbis-ZZ was digested from the vector sup-
plied by Dr. Irvin S.Y. Chen and inserted into the recom-
binant VSV genome between the genes for VSV-M and
EGFP. This new recombinant genome as well as pBS-P,
pBS-L, pBS-N, and pBS-G were transfected into COS-7
cells and infected with vTF-7. The pBS-G vector was in-
cluded to make a virus that contained VSV-G on its surface
and could be amplified on BHK cells. Viruses were har-
vested from the supernatant 2 days later and amplified on
unmodified BHK21 cells. The virus harvested from this
supernatant contained the gene for Sindbis-ZZ in the ge-
nome. The only surface gp on this virus was Sindbis-ZZ.
Titers were determined as detailed above except that green
cells were counted at 8 h to count only input virus and avoid
counting newly produced virus.
Growth of replicating virus was determined by incubat-
ing virus and indicator cell line in one well of a six-well tray
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at an m.o.i.  0.05 for 2 h, washing three times, replacing
the media, and counting green cells in an inverted fluores-
cent microscope every 6 h for 24 h. The number of infected
cells could not be accurately counted after this time because
of cell clumping and lysis of early infected cells. Cytopathic
effect (CPE) was determined by incubating virus and indi-
cator cell line in one well of a six-well tray at m.o.i.  10
for 2 h, washing, replacing the media, and harvesting all
cells after 1 day. The number of live cells in the virus-
infected well was divided by the number of live cells in a
no-virus control well and multiplied by 100 to determine the
percentage of living cells following treatment. The percent-
age of CPE was 100 minus this number.
Analysis of the protein composition of pseudotype VSV
VSV pseudotypes were created by transfecting BHK-21
with DNA encoding either Sindbis gp, Sindbis-ZZ gp, or
VSV-G gp. Preparation of 35S-labeled virus was performed
as previously described with modifications (Whitaker-
Dowling et al., 1983). Twenty-four hours after transfection,
the media was removed from each well and replaced with 1
ml of cysteine/methionine-free media (Cat. no. 19050-121,
Gibco/BRL) containing 20 l of [35S]methionine
(Trans35S-LABEL, 10 mCi/ml, ICN Biochemicals, Irvine,
CA, Cat. no. 51006). Forty-eight hours after transfection,
the cells were infected by the addition of VSV-EGFP-G
coated with G gp at an m.o.i. of 5. Seventy-two hours after
transfection, the media containing the radiolabeled virus
was harvested, and the cell debris was removed by centrif-
ugation at 1000 g for 5 min. The virus in the supernatent
was then pelleted by ultracentrifugation in a swinging
bucket rotor at 80,000 g for 2 h. The virus pellets were
resuspended in 200 l of complete medium and layered on
a 10–40% sucrose gradient containing 10 mM Tris pH 7.4,
1 M NaCl, and 1 mM EDTA. The gradient was subjected to
ultracentrifugation in a swinging bucket rotor at 35,000 g
for 90 min. The radiolabeled viral band was collected and
diluted to 33 ml with serum-free medium and repelleted by
ultracentrifugation as described. The virus pellet was resus-
pended in 200 l of serum-free medium. The purified ra-
diolabeled virus was diluted 1:1 with 2 Laemmli sample
buffer and subjected to analysis by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis using 10% acrylamide
containing 0.09% bis-acrylamide (Laemmli, 1970). The gel
was dried under vacuum and examined by autoradiography.
Viral bands were identified by their molecular weights.
Similar techniques were used to prepare 35S-labeled recom-
binant-replicating VSV whose surface gp was Sindbis-ZZ.
Two hours after infection of SKBR3 cells at m.o.i.  6, the
media was removed and replaced with 1 ml of cysteine/
methionine-free media containing 20 l of [35S]methionine
(Trans35S-LABEL, 10 mCi/ml). The media containing the
radiolabeled virus was harvested 24 h after infection.
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